184 related articles for article (PubMed ID: 16505486)
21. Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor.
Shimamura M; Matsuda M; Ando Y; Koishi R; Yasumo H; Furukawa H; Shimomura I
Biochem Biophys Res Commun; 2004 Sep; 322(3):1080-5. PubMed ID: 15336575
[TBL] [Abstract][Full Text] [Related]
22. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
Tagami T; Jameson JL
Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
[TBL] [Abstract][Full Text] [Related]
23. Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities.
Gunn KH; Gutgsell AR; Xu Y; Johnson CV; Liu J; Neher SB
J Biol Chem; 2021; 296():100312. PubMed ID: 33482195
[TBL] [Abstract][Full Text] [Related]
24. Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action.
Araki O; Ying H; Furuya F; Zhu X; Cheng SY
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16251-6. PubMed ID: 16260719
[TBL] [Abstract][Full Text] [Related]
25. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma.
Chen RN; Huang YH; Yeh CT; Liao CH; Lin KH
Cancer Res; 2008 Mar; 68(6):1697-706. PubMed ID: 18339849
[TBL] [Abstract][Full Text] [Related]
26. Specificity of thyroid hormone receptor subtype and steroid receptor coactivator-1 on thyroid hormone action.
Sadow PM; Chassande O; Gauthier K; Samarut J; Xu J; O'Malley BW; Weiss RE
Am J Physiol Endocrinol Metab; 2003 Jan; 284(1):E36-46. PubMed ID: 12388168
[TBL] [Abstract][Full Text] [Related]
27. Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR.
Matsusue K; Miyoshi A; Yamano S; Gonzalez FJ
Mol Cell Endocrinol; 2006 Aug; 256(1-2):23-33. PubMed ID: 16806672
[TBL] [Abstract][Full Text] [Related]
28. Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.
Carr FE; Tai PW; Barnum MS; Gillis NE; Evans KG; Taber TH; White JH; Tomczak JA; Jaworski DM; Zaidi SK; Lian JB; Stein JL; Stein GS
Endocrinology; 2016 Aug; 157(8):3278-92. PubMed ID: 27253998
[TBL] [Abstract][Full Text] [Related]
29. Thyroid hormone receptor inhibits hepatoma cell migration through transcriptional activation of Dickkopf 4.
Chi HC; Liao CH; Huang YH; Wu SM; Tsai CY; Liao CJ; Tseng YH; Lin YH; Chen CY; Chung IH; Wu TI; Chen WJ; Lin KH
Biochem Biophys Res Commun; 2013 Sep; 439(1):60-5. PubMed ID: 23958302
[TBL] [Abstract][Full Text] [Related]
30. The IkappaBalpha gene is a peroxisome proliferator-activated receptor cardiac target gene.
Buroker NE; Barboza J; Huang JY
FEBS J; 2009 Jun; 276(12):3247-55. PubMed ID: 19438714
[TBL] [Abstract][Full Text] [Related]
31. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity.
Fujimoto K; Koishi R; Shimizugawa T; Ando Y
Exp Anim; 2006 Jan; 55(1):27-34. PubMed ID: 16508209
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression.
Guigon CJ; Kim DW; Zhu X; Zhao L; Cheng SY
Endocrinology; 2010 Nov; 151(11):5528-36. PubMed ID: 20844001
[TBL] [Abstract][Full Text] [Related]
33. Direct regulation of androgen receptor-associated protein 70 by thyroid hormone and its receptors.
Tai PJ; Huang YH; Shih CH; Chen RN; Chen CD; Chen WJ; Wang CS; Lin KH
Endocrinology; 2007 Jul; 148(7):3485-95. PubMed ID: 17412801
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant Beta receptor.
Zhang XY; Kaneshige M; Kamiya Y; Kaneshige K; McPhie P; Cheng SY
Mol Endocrinol; 2002 Sep; 16(9):2077-92. PubMed ID: 12198244
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.
Jeyakumar M; Tanen MR; Bagchi MK
Mol Endocrinol; 1997 Jun; 11(6):755-67. PubMed ID: 9171239
[TBL] [Abstract][Full Text] [Related]
37. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis.
Furumoto H; Ying H; Chandramouli GV; Zhao L; Walker RL; Meltzer PS; Willingham MC; Cheng SY
Mol Cell Biol; 2005 Jan; 25(1):124-35. PubMed ID: 15601836
[TBL] [Abstract][Full Text] [Related]
38. Both thyroid hormone receptor (TR)beta 1 and TR beta 2 isoforms contribute to the regulation of hypothalamic thyrotropin-releasing hormone.
Dupré SM; Guissouma H; Flamant F; Seugnet I; Scanlan TS; Baxter JD; Samarut J; Demeneix BA; Becker N
Endocrinology; 2004 May; 145(5):2337-45. PubMed ID: 14726446
[TBL] [Abstract][Full Text] [Related]
39. Feedback on hypothalamic TRH transcription is dependent on thyroid hormone receptor N terminus.
Guissouma H; Dupré SM; Becker N; Jeannin E; Seugnet I; Desvergne B; Demeneix BA
Mol Endocrinol; 2002 Jul; 16(7):1652-66. PubMed ID: 12089358
[TBL] [Abstract][Full Text] [Related]
40. A novel mutation (E333D) in the thyroid hormone beta receptor causing resistance to thyroid hormone syndrome.
Maraninchi M; Bourcigaux N; Dace A; El-Yazidi C; Malezet-Desmoulins C; Krempf M; Torresani J; Margotat A
Exp Clin Endocrinol Diabetes; 2006 Nov; 114(10):569-76. PubMed ID: 17177139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
